GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (STU:260) » Definitions » EV-to-Revenue

Centessa Pharmaceuticals (STU:260) EV-to-Revenue : 119.19 (As of May. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Centessa Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Centessa Pharmaceuticals's enterprise value is €748.97 Mil. Centessa Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €6.28 Mil. Therefore, Centessa Pharmaceuticals's EV-to-Revenue for today is 119.19.

The historical rank and industry rank for Centessa Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

STU:260' s EV-to-Revenue Range Over the Past 10 Years
Min: 71.09   Med: 117   Max: 149.27
Current: 120.83

During the past 5 years, the highest EV-to-Revenue of Centessa Pharmaceuticals was 149.27. The lowest was 71.09. And the median was 117.00.

STU:260's EV-to-Revenue is ranked worse than
84.84% of 1042 companies
in the Biotechnology industry
Industry Median: 8.215 vs STU:260: 120.83

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-23), Centessa Pharmaceuticals's stock price is €7.80. Centessa Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.06. Therefore, Centessa Pharmaceuticals's PS Ratio for today is 121.88.


Centessa Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Centessa Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centessa Pharmaceuticals EV-to-Revenue Chart

Centessa Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
- - - - 89.64

Centessa Pharmaceuticals Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 89.64 144.66

Competitive Comparison of Centessa Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Centessa Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Centessa Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Centessa Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Centessa Pharmaceuticals's EV-to-Revenue falls into.



Centessa Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Centessa Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=748.972/6.284
=119.19

Centessa Pharmaceuticals's current Enterprise Value is €748.97 Mil.
Centessa Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Centessa Pharmaceuticals  (STU:260) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Centessa Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=7.80/0.064
=121.88

Centessa Pharmaceuticals's share price for today is €7.80.
Centessa Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.06.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Centessa Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Centessa Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Centessa Pharmaceuticals (STU:260) Business Description

Traded in Other Exchanges
Address
1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

Centessa Pharmaceuticals (STU:260) Headlines

No Headlines